EAM
ITCI

Eagle Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Eagle Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$57M Buy
624,759
+353,723
+131% +$26.6M 0.29% 111
2024
Q2 		$18.4M Sell
271,036
-81,306
-23% -$5.64M 0.1% 195
2024
Q1 		$24.1M Sell
352,342
-83,376
-19% -$5.73M 0.12% 166
2023
Q4 		$31.2M Buy
435,718
+22,628
+5% +$1.3M 0.17% 146
2023
Q3 		$21.5M Buy
413,090
+14,290
+4% +$833K 0.13% 171
2023
Q2 		$25.3M Buy
398,800
+172,147
+76% +$10.7M 0.14% 159
2023
Q1 		$12.3M Sell
226,653
-40,183
-15% -$1.94M 0.07% 218
2022
Q4 		$13.8M Buy
266,836
+11,879
+5% +$595K 0.08% 200
2022
Q3 		$11.9M Sell
254,957
-6,500
-2% -$340K 0.08% 214
2022
Q2 		$14.9M Buy
+261,457
New +$14.8M 0.09% 201

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eagle Asset Management's ITCI Position: Q3 2024 in Review

Eagle Asset Management increased its Intra-Cellular Therapies Inc. (ITCI) stake by 131% in Q3 2024, buying an estimated $26.6M and bringing the position to 624,759 shares worth $57M. The position accounts for 0.29% of the portfolio, ranked #111.

Eagle Asset Management first reported a position in ITCI in Q2 2022 and has held it in 10 quarters since. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Eagle Asset Management held 624,759 shares of Intra-Cellular Therapies Inc. worth $57M as of Q3 2024.
  • Eagle Asset Management bought 353,723 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $26.6M.
  • Intra-Cellular Therapies Inc. made up 0.29% of Eagle Asset Management's portfolio in Q3 2024, its #111 holding.
  • Eagle Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and has held it in 10 quarters since.
  • 354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.